<DOC>
	<DOCNO>NCT02431286</DOCNO>
	<brief_summary>The objective study investigate aprepitant association palonosetron dexamethasone could reduce incidence PONV high-risk patient symptom , undergo cancer surgery mastectomy .</brief_summary>
	<brief_title>Palonosetron Associated Aprepitant Prophylaxis PONV</brief_title>
	<detailed_description>Postoperative nausea vomiting ( PONV ) common anesthetic complication occur approximately 30 % surgical population reach 70 % high risk patient PONV . Advances make prevent PONV , incidence still high certain group patient . In high risk patient , pharmacologic intervention consist multimodal therapy , target different mechanism action . The objective study investigate aprepitant association palonosetron dexamethasone could reduce incidence PONV high-risk patient symptom , undergo cancer surgery mastectomy . METHODS : randomize double blind clinical trial . Female high-risk patient PONV ( Apfel score 3 4 ) schedule mastectomy agree study sign informed consent , randomly distribute one two group : Group A , aprepitant 80 mg per o one hour surgery Group B receive placebo route one hour surgery , blind way . After induction anesthesia , dexamethasone 4 mg palonosetron 0,075mg intravenously administer patient . After end surgery , patient-controlled analgesia ( PCA ) device intravenously inserted patient . In postoperative period , patient evaluate nausea , vomit pain intensity recovery room 24 hour</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>patient submit breast cancer surgery non smoker contraindication one drug mental disease inability understand method refusal participate research</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>nausea vomiting , postoperative</keyword>
	<keyword>emesis , postoperative</keyword>
</DOC>